Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shanghai
Clinical trial register · China

Clinical Trials in Shanghai, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 5576 Shanghai 3879 Guangzhou 3345 Hangzhou 1819 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Fudan University462 Ruijin Hospital282 Shanghai Zhongshan Hospital169 RenJi Hospital133 Children's Hospital of Fudan University84
Site location
Beijing5576 Shanghai3879 Guangzhou3345 Hangzhou1819 Wuhan1343
All 625 locations
Target enrolment
to

Trials with a site in Shanghai

3879 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
144
Beijing, Guangzhou, Zhengzhou, Shenyang, Jinan, Shanghai
2024-07-24
Recruiting
PulseSelect™ PFA Global Registry
NCT06393920Atrial Fibrillation
Medtronic Cardiac Ablation Solutions
Observational
1,950
Beijing, Fuzhou, Harbin, Kunming, Nanjing, Shanghai, Shenzhen, Ürümqi
2024-07-23
Recruiting
Ruijin Hospital
Observational
150
Shanghai
2024-07-23
Active, closed
Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC
NCT06376084Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Respiratory Tract Neoplasms, Thoracic Neoplasms
AstraZeneca
Observational
532
Shanghai
2024-07-23
Recruiting
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 1
108
Shanghai
2024-07-23
Active, closed
Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
NCT06054113B Precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia
DrugBlinatumomab
Amgen
Phase 2
18
Hefei, Chongqing, Guangzhou, Wuhan, Suzhou, Shanghai, Tianjin
2024-07-23
Recruiting
The Impact of Airway Allergic Diseases on Children's and Parents' Quality of Life
NCT06535087Pediatric Asthma, Rhinitis, Allergic, Quality of Life
Wenjing Zhou
Observational
600
Shanghai
2024-07-20
Recruiting
Shanghai Zhongshan Hospital
Observational
50
Shanghai
2024-07-19
Recruiting
The Application Value of 68Ga-grazytracer PET in Immunotherapy for Stage III Non-small-cell Lung Cancer
NCT06623487Carcinoma, Non-Small-Cell Lung, PET / CT, Neoadjuvant Immunotherapy
Ruijin Hospital
Observational
30
Shanghai
2024-07-19
Recruiting
GlaxoSmithKline
Phase 3
150
Guangzhou, Shanghai, Tianjin
2024-07-19
Active, closed
Huashan Hospital
Not applicable
372
Shanghai
2024-07-19
Recruiting
Fudan University
Observational
48
Shanghai
2024-07-18
Recruiting
Fudan University
Phase 1
9
Shanghai
2024-07-18
Active, closed
Shanghai Jiao Tong University School of Medicine
Phase 1
20
Shanghai
2024-07-17
Recruiting
Ruijin Hospital
Early Phase 1
20
Shanghai
2024-07-16
Recruiting
Jiang Long
Phase 2
40
Shanghai
2024-07-16
Recruiting
Shanghai Changzheng Hospital
Phase 1/2
40
Shanghai
2024-07-16
Recruiting
NGGT (Suzhou) Biotechnology Co., Ltd.
Phase 1/2
18
Bengbu, Shanghai
2024-07-16
Recruiting
Fudan University
Observational
1,000
Shanghai
2024-07-15
Not yet open
Shanghai Zhongshan Hospital
Not applicable
338
Shanghai
2024-07-15
Recruiting
RenJi Hospital
Early Phase 1
21
Shanghai
2024-07-15
Recruiting
Children's Hospital of Fudan University
Not applicable
336
Shanghai
2024-07-13
Recruiting
Children's Hospital of Fudan University
Not applicable
324
Shanghai
2024-07-13
Recruiting
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 2/3
132
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Jinan, Shanghai
2024-07-12
Recruiting
Fudan University
Phase 3
124
Shanghai
2024-07-11
Recruiting
Nanjing Immunophage Biotech Co., Ltd
Phase 1/2
60
Shanghai
2024-07-11
Recruiting
Ruijin Hospital
Phase 3
78
Shanghai
2024-07-10
Recruiting
Fudan University
Phase 2
74
Shanghai
2024-07-10
Recruiting
Colorado Prevention Center
Phase 3
1,500
Guangzhou, Changsha, Jinan, Shanghai, Taiyuan, Xian City, Chengdu, Tianjin
2024-07-09
Recruiting
Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC
NCT06235203Recurrent Nasopharyngeal Carcinoma
Eye & ENT Hospital of Fudan University
Phase 3
154
Shanghai, Fuzhou, Nanning, Shenzhen
2024-07-09
Recruiting
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 or 2 Systemic Treatment Regimens
NCT06127407Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
DrugIvosidenib
Servier Bio-Innovation LLC
Phase 3
156
Guangzhou, Zhengzhou, Wuhan, Changsha, Shang'ai, Shanghai, Chengdu, Hangzhou
2024-07-09
Active, closed
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
47
Shanghai
2024-07-05
Recruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1
150
Shanghai
2024-07-04
Recruiting
Grit Biotechnology
Not applicable
18
Shanghai
2024-07-04
Recruiting
Fudan University
Phase 2
52
Shanghai
2024-07-03
Recruiting
A Study of FZ-AD005 in Patients With Advanced Solid Tumors
NCT06424665Advanced Solid Tumor, SCLC(Small Cell Lung Cancer) or LCNEC (Large Cell Neuroendocrine Carcinoma)
DrugFZ-AD005
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Phase 1
162
Changsha, Shanghai, Hangzhou
2024-07-03
Active, closed
Shanghai Vitalgen BioPharma Co., Ltd.
Phase 2/3
13
Shanghai
2024-07-02
Recruiting
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2
56
Shanghai
2024-07-02
Recruiting
First Affiliated Hospital of the Chinese People's Liberation Army Naval Medical University
Not applicable
15
Shanghai
2024-07-02
By invitation
Real-world Study of Acalabrutinib
NCT06767891Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Ruijin Hospital
Observational
160
Shanghai
2024-07-02
Recruiting
Fudan University
Observational
80
Shanghai
2024-07-02
Recruiting
A Phase I Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors
NCT07923214Advanced Solid Tumors, Breast Cancer, Ovarian Cancer, Gastric Cancer
Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd.
Phase 1
30
Fuzhou, Dalian, Shanghai, Chengdu
2024-07-02
Recruiting
Fudan University
Phase 2
54
Shanghai
2024-07-01
Recruiting
DRug-coAted Balloon Compared With cuttinG balloON in Treatment of Arteriovenous Fistula Stenosis
NCT06527963Arteriovenous Fistula, Angioplasty, Balloon, Hemodialysis Access Failure
RenJi Hospital
Observational
180
Zhengzhou, Nanjing, Shanghai
2024-07-01
Active, closed
Fudan University
Phase 2
41
Shanghai
2024-07-01
Recruiting
Risk Evaluation by COronary Imaging and Artificial intelliGence Based fuNctIonal analyZing tEchniques - IV
NCT06793787Coronary Artery Disease, Coronary Atheroscleroses, Acute Coronary Syndromes (ACS), Chronic Coronary Syndrome
Ruijin Hospital
Observational
200
Shanghai
2024-07-01
Active, closed
Ruijin Hospital
Phase 3
250
Wuhan, Shanghai, Hangzhou
2024-07-01
Recruiting
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Observational
600
Shanghai
2024-07-01
Recruiting
Risk Evaluation by COronary Imaging and Artificial intelliGence Based fuNctIonal analyZing tEchniques - III
NCT06793774Coronary Artery Disease, Coronary Atheroscleroses, Acute Coronary Syndromes (ACS)
Ruijin Hospital
Observational
300
Shanghai
2024-07-01
Recruiting
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT06465069Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
DrugPembrolizumab
Eli Lilly and Company
Phase 1
460
Beijing, Guangzhou, Shanghai
2024-07-01
Not yet open
Changhai Hospital
Observational
1,200
Shanghai
2024-07-01
Recruiting
Segmentectomy for Solid-dominant Lung Cancer
NCT06634966Segmentectomy, Lung Adenocarcinoma
Fudan University
Phase 3
277
Shanghai
2024-07-01
Recruiting
FeNO Observation Study in ICU Patients With ARS
NCT06680895Compare the Concentration of Exhaled Nitric Oxide in Patients With Different Severity of RF
Shanghai Zhongshan Hospital
Observational
1,000
Shanghai
2024-07-01
Active, closed
Shanghai Changzheng Hospital
Phase 2
15
Shanghai
2024-07-01
Not yet open
Shanghai Zhongshan Hospital
Observational
358
Shanghai
2024-07-01
Recruiting
Calcium Folinate Treatment of Spastic Paraplegia 56
NCT06478238Hereditary Spastic Paraplegia
DrugCalcium folinate
Shanghai 6th People's Hospital
Early Phase 1
10
Shanghai
2024-07-01
Not yet open
Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC
NCT06456138KRAS Mutation-Related Tumors, Advanced Lung Cancer, Refractory Tumor
DrugsTrametinib·Anlotinib·Tislelizumab
Shanghai Chest Hospital
Phase 1/2
60
Shanghai
2024-07-01
Not yet open
Shanghai Zhongshan Hospital
Observational
19
Shanghai
2024-07-01
Recruiting
The Efficacy and Safety of HCQ Plus TPO-RA in ANA Positive ITP
NCT06479291Immune Thrombocytopenia With Positive ANA Antibodies
DrugsEltrombopag·Hydroxychloroquine
Yunfeng Cheng
Not applicable
126
Shanghai
2024-07
Not yet open
Shanghai Zhongshan Hospital
Phase 2
128
Shanghai
2024-07
Recruiting
Ruijin Hospital
Phase 1
32
Shanghai
2024-07
Not yet open
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
54
Beijing, Zhengzhou, Changsha, Changchun, Jinan, Shanghai, Taiyuan, Tianjin
2024-07
Active, closed
Guangzhou Medical University
Phase 1/2
45
Huizhou, Beijing, Shanghai
2024-06-30
Recruiting
Ruijin Hospital
Phase 4
86
Shanghai
2024-06-30
Recruiting
Differentiation of Benign and Malignant Pulmonary Nodules by Volatile Organic Compounds in Human Exhaled Breath
NCT06518655Pulmonary Nodules, Multiple, Pulmonary Nodules, Solitary, Lung Cancer
ChromX Health
Observational
3,000
Beijing, Foshan, Guangzhou, Wuhan, Shanghai, Chengdu
2024-06-30
Recruiting
Ruijin Hospital
Not applicable
212
Shanghai
2024-06-30
Recruiting
Boehringer Ingelheim
Phase 1/2
910
Changchun, Hangzhou, Harbin, Nanjing, Shanghai, Tianjin, Zhengzhou
2024-06-28
Recruiting
Grit Biotechnology
Not applicable
18
Shanghai
2024-06-28
Recruiting
Shanghai Zhongshan Hospital
Phase 4
124
Shanghai
2024-06-28
Recruiting
RenJi Hospital
Not applicable
176
Shanghai
2024-06-28
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
21
Shanghai
2024-06-27
Recruiting
Changhai Hospital
Phase 1
72
Shanghai
2024-06-27
Recruiting
Efficacy of Hi-tACS for Schizophrenia Negative Symptoms
NCT06888726Schizophrenia; Negative Type, Transcranial Alternating Current Stimulation
Shanghai Mental Health Center
Not applicable
60
Shanghai
2024-06-27
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
140
Guangzhou, Zhuhai, Chengde, Harbin, Changsha, Changzhou, Binzhou, Shanghai
2024-06-27
Recruiting
Beijing 302 Hospital
Phase 2
140
Lanzhou, Guangzhou, Sanya, Wuhan, Shanghai, Kashgar, Beijing
2024-06-27
Recruiting
Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC
NCT06494943Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
DrugsCis-platinum·Sintilimab·Paclitaxel
Fudan University
Phase 1/2
27
Shanghai
2024-06-26
Recruiting
Adjuvant vs Surgery Only in Early-stage Recurrent NPC
NCT06228079Recurrent Nasopharyngeal Carcinoma
Eye & ENT Hospital of Fudan University
Phase 3
176
Shanghai, Fuzhou, Nanning, Shenzhen
2024-06-25
Recruiting
Haisco Pharmaceutical Group Co., Ltd.
Phase 1
316
Beijing, Fuzhou, Guangzhou, Nanning, Zhengzhou, Changsha, Nanjing, Shanghai
2024-06-25
Recruiting
Evaluate LAE102 in Healthy and Overweight/Obese Subjects
NCT06493084Overweight and Obese Volunteers
DrugLAE102
Laekna Limited
Phase 1
160
Shanghai
2024-06-25
Recruiting
A Trial to Evaluate the Effect of Applying Leukapheresis to Enrich CTCs in mPCa Patients
NCT06469710Prostate Cancer, Circulating Tumor Cell, Leukapheresis
RenJi Hospital
Observational
50
Shanghai
2024-06-25
Recruiting
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 3
480
Shanghai
2024-06-24
Recruiting
Avistone Biotechnology Co., Ltd.
Phase 1
63
Beijing, Harbin, Zhengzhou, Jinan, Shanghai
2024-06-24
Active, closed
LaNova Medicines Zhejiang Co., Ltd.
Phase 3
387
Beijing, Shanghai
2024-06-24
Recruiting
Changhai Hospital
Early Phase 1
36
Shanghai
2024-06-21
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
418
Shanghai
2024-06-21
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
220
Beijing, Fuzhou, Wuhan, Changsha, Shanghai, Chengdu
2024-06-20
Active, closed
Fudan University
Phase 2
58
Shanghai
2024-06-20
Recruiting
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 2
116
Shanghai
2024-06-19
Not yet open
Shanghai Chest Hospital
Phase 2
34
Shanghai
2024-06-19
Recruiting
L & L Bio Co., Ltd., Ningbo, China
Phase 1/2
194
Shanghai
2024-06-19
Recruiting
Children's Hospital of Fudan University
Not applicable
5
Shanghai
2024-06-18
Recruiting
Jun Zhou
Phase 1
90
Fuzhou, Anyang, Jinan, Shanghai
2024-06-18
Recruiting
AMT-676 in Patients With Advanced Solid Tumors
NCT06400485Advanced Solid Tumors
DrugAMT-676
Multitude Therapeutics Inc.
Early Phase 1
24
Fuzhou, Guangzhou, Shanghai, Chengdu, Hangzhou
2024-06-18
Recruiting
CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies
NCT06316856T-Cell Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia, T-cell Malignancies
Beijing GoBroad Hospital
Phase 1/2
54
Beijing, Shanghai, Chengdu
2024-06-18
Active, closed
Hoffmann-La Roche
Phase 3
68
Beijing, Chengdu, Guangzhou, Harbin, Qingdao, Shanghai, Shenyang, Taiyuan
2024-06-17
Recruiting
3H (Suzhou) Pharmaceuticals Co., Ltd.
Phase 1/2
130
Beijing, Shanghai
2024-06-17
Recruiting
Fudan University
Phase 1/2
130
Shanghai
2024-06-17
Recruiting
Shanghai Chest Hospital
Phase 2
60
Shanghai
2024-06-17
Not yet open
Shanghai Simnova Biotechnology Co.,Ltd.
Phase 1
50
Shanghai
2024-06-15
Recruiting
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1
556
Shanghai
2024-06-15
Recruiting
Ruijin Hospital
Observational
30
Shanghai
2024-06-15
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
66
Shanghai
2024-06-13
Recruiting
Liangjing Lu
Phase 1
6
Shanghai
2024-06-12
Active, closed
Fudan University
Phase 3
184
Shanghai
2024-06-11
Recruiting
First Affiliated Hospital of Zhejiang University
Phase 2
30
Hangzhou, Harbin, Hefei, Jinhua, Nanchang, Shanghai, Ürümqi, Xi'an
2024-06-11
Recruiting
Sinotau Pharmaceutical Group
Phase 2/3
85
Shanghai
2024-06-11
Active, closed
GlaxoSmithKline
Phase 3
88
Chengdu, Hangzhou, Hefei, Nanjing, Shanghai
2024-06-10
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
46
Shanghai
2024-06-07
Recruiting
Shanghai Changzheng Hospital
Early Phase 1
10
Shanghai
2024-06-06
Recruiting
Shanghai Children's Medical Center
Not applicable
200
Shanghai
2024-06-06
Recruiting
AstraZeneca
Observational
850
Beijing, Changsha, Chengdu, Guangzhou, Hefei, Nanjing, Nanning, Shanghai
2024-06-05
Not yet open
Shanghai Chest Hospital
Not applicable
10
Shanghai
2024-06-05
Recruiting
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
62
Shanghai
2024-06-05
Recruiting
Juventas Cell Therapy Ltd.
Observational
200
Beijing, Guangzhou, Zhengzhou, Wuhan, Xuzhou, Jinan, Shanghai, Chengdu
2024-06-05
Recruiting
A Trail of Sperstent® Used for Residual Lesions of Femoropopliteal Arteries
NCT06539689Peripheral Arterial Disease, Stenosis, Dissection
FrontAce Scientific Co., Ltd
Not applicable
240
Beijing, Chongqing, Shijiazhuang, Zhengzhou, Wuhan, Nanjing, Nantong, Shanghai
2024-06-04
Active, closed
Jiangsu HengRui Medicine Co., Ltd.
Phase 2
59
Shanghai
2024-06-04
Not yet open
Shanghai Municipal Hospital of Traditional Chinese Medicine
Not applicable
170
Shanghai
2024-06-01
Recruiting
RenJi Hospital
Observational
180
Zhengzhou, Nanjing, Shanghai
2024-06-01
Not yet open
Ruijin Hospital
Phase 3
220
Shanghai
2024-06-01
Recruiting
Changhai Hospital
Not applicable
72
Shanghai
2024-06-01
Recruiting
Shanghai Changzheng Hospital
Phase 2
15
Shanghai
2024-06-01
Recruiting
ZhanYJ
Not applicable
176
Shanghai
2024-06-01
By invitation
Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT)
NCT06963060Gallbladder Cancer, Cholangiocarcinoma
Wei Gong
Phase 2
44
Shanghai
2024-06-01
Not yet open
Study on the Efficacy of Long-term Drainage of Subdural Effusion After Decompressive Craniectomy
NCT06391203Traumatic Brain Injury, Decompressive Craniectomy, Subdural Effusion
RenJi Hospital
Not applicable
160
Shanghai
2024-06-01
Recruiting
Fudan University
Phase 2
80
Shanghai
2024-06-01
Recruiting
CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL
NCT06445803Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent
Rong Tao
Phase 1
48
Nanchang, Shanghai
2024-05-31
Recruiting
Shanghai RAAS Blood Products Co., Ltd.
Phase 1/2
76
Changsha, Hefei, Jinan, Lanzhou, Shanghai, Taiyuan, Tianjin, Xi'an
2024-05-31
Recruiting
A Cohort Study in Newly Diagnosed MZL
NCT06449885Marginal Zone Lymphoma
Fudan University
Observational
2,500
Shanghai
2024-05-30
Recruiting
Lifetech Scientific (Shenzhen) Co., Ltd.
Not applicable
103
Beijing, Changsha, Chengdu, Fuzhou, Hanzhou, Kunming, Nanjing, Shanghai
2024-05-30
Recruiting
A Study of GC203 TIL in Advanced Malignant Solid Tumors
NCT06375187Solid Tumor, Gynecologic Cancer, Breast Cancer, Gastrointestinal Cancer
DrugEngineering Tumor Infiltrating Lymphocytes
Shanghai Juncell Therapeutics
Phase 1
18
Shanghai
2024-05-29
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
52
Shanghai
2024-05-29
Active, closed
A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
NCT06470438Lymphoma, Non-Hodgkin, Refractory B-Cell NHL, Relapsed B-cell NHL
Janssen Research & Development, LLC
Phase 1
58
Beijing, Guangzhou, Hangzhou, Shanghai, Tianjin
2024-05-28
Recruiting
The Liquid Embolic Agent for the Treatment of Brain Arteriovenous Malformation
NCT07314047Brain Arteriovenous Malformation, Arteriovenous Fistula
MicroPort NeuroTech Co., Ltd.
Not applicable
116
Shanghai
2024-05-28
Recruiting
Lei-Miao Yin
Observational
120
Shanghai
2024-05-28
Recruiting
Prospective Clinical Trial for Children With TCRαβ Depleted vs Traditional Haplo Identicle HSCT
NCT06423131Graft-Versus-Host Disease, Hematopoietic Stem Cell Transplantation, Child, Only, Haploidentical Hematopoietic Stem Cell Transplantation
Sijia Gu
Not applicable
110
Shanghai
2024-05-26
Recruiting
Fudan University
Phase 2
52
Shanghai
2024-05-24
Recruiting
Shanghai Zhongshan Hospital
Not applicable
322
Shanghai
2024-05-24
Recruiting
RenJi Hospital
Early Phase 1
20
Shanghai
2024-05-24
Recruiting
Ruijin Hospital
Phase 2
26
Shanghai
2024-05-22
Recruiting
Clinical Study of HIFU for Localized Prostate Cancer
NCT06362577Localized Prostate Cancer
RenJi Hospital
Observational
60
Shanghai
2024-05-21
Recruiting
Shanghai Jiao Tong University School of Medicine
Phase 2/3
90
Hefei, Fuzhou, Shanghai, Ningbo
2024-05-21
Recruiting
Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.
Phase 3
692
Shanghai
2024-05-20
Recruiting
AstraZeneca
Phase 3
440
Beijing, Bengbu, Chengdu, Chongqing, Hohhot, Mianyang, Shanghai, Shantou
2024-05-20
Active, closed
Avistone Biotechnology Co., Ltd.
Phase 1
40
Shanghai
2024-05-19
Recruiting
Thalidomide Therapy for VEOIBD
NCT06382519Inflammatory Bowel Diseases
DrugThalidomide
Children's Hospital of Fudan University
Observational
40
Shanghai
2024-05-15
Not yet open
Guangdong Ruishun Biotech Co., Ltd
Phase 1
24
Beijing, Nanjing, Shanghai
2024-05-15
Recruiting
Ruijin Hospital
Observational
1,000
Shanghai
2024-05-15
Active, closed
Changhai Hospital
Observational
120
Shanghai
2024-05-15
Recruiting
Shanghai Zhongshan Hospital
Observational
240
Shanghai
2024-05-15
Recruiting
Fudan University
Phase 3
210
Shanghai
2024-05-15
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
30
Beijing, Guangzhou, Shanghai, Shenzhen
2024-05-14
Recruiting
Changhai Hospital
Phase 2
67
Shanghai
2024-05-12
Recruiting
Grit Biotechnology
Not applicable
32
Shanghai
2024-05-12
Recruiting
Shanghai Institute Of Biological Products
Phase 1
144
Shanghai
2024-05-09
Recruiting
Fudan University
Phase 2
60
Shanghai
2024-05-08
Recruiting
Shanghai Cell Therapy Group Co.,Ltd
Early Phase 1
20
Shanghai
2024-05-07
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
65
Hefei, Lanzhou, Guangzhou, Nanning, Shijiazhuang, Xiangyang, Taian, Shanghai
2024-05-07
Not yet open
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer
NCT06404736Early Breast Cancer, Neoadjuvant Therapy, TNBC, Triple Negative Breast Cancer
DrugsAlbumin-Bound Paclitaxel·Carboplatin
Fudan University
Phase 2
73
Shanghai
2024-05-07
Recruiting
RenJi Hospital
Not applicable
12
Shanghai
2024-05-07
Recruiting
The Clinical Study of Post-operative Proton Radiotherapy for Thymus Tumor
NCT06311968Thymus Epithelial Tumor, Proton Radiotherapy, Radiation Toxicity
Jian Chen
Phase 2
55
Shanghai
2024-05-06
By invitation
Shanghai Mental Health Center
Not applicable
35
Shanghai
2024-05-05
Recruiting
Dalpiciclib in HR+/HER2- ABC
NCT06301438Advanced Breast Cancer
DrugDalpiciclib
RenJi Hospital
Observational
103
Shanghai
2024-05-03
Recruiting
Research on Body Voice AI Recognition System for Children's Health Management
NCT06542120Congenital Heart Disease, Bronchopneumonia, Abdominal Disease
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Observational
30,000
Wuhan, Changsha, Shanghai, Kunming
2024-05-01
Recruiting
Fudan University
Not applicable
684
Shanghai
2024-05-01
Recruiting
A Multimodal Prospective Cohort Study of Parkinsonism
NCT07553845Parkinsonism, REM Sleep Behavior Disorder
Ruijin Hospital
Observational
640
Shanghai
2024-05-01
Recruiting
Fudan University
Phase 4
592
Shanghai
2024-05-01
Recruiting
Renovated Prediction Model for Difficult Transoral and Submental Endoscopic Thyroidectomy
NCT06738888Thyroid Cancer, Thyroid Diseases, Thyroid Nodule
Shanghai 6th People's Hospital
Observational
300
Shanghai
2024-05-01
Recruiting
Ruijin Hospital
Phase 3
356
Shanghai
2024-05-01
Recruiting
Huashan Hospital
Phase 3
58
Shanghai
2024-05-01
Recruiting
Ruijin Hospital
Phase 2
56
Shanghai
2024-05-01
Not yet open
Changhai Hospital
Not applicable
200
Guangzhou, Suzhou, Wuxi, Ningbo, Shanghai
2024-05-01
Recruiting
Children's Hospital of Fudan University
Not applicable
180
Shanghai
2024-05-01
Recruiting
Ruijin Hospital
Phase 2
24
Shanghai
2024-05
Not yet open
Fudan University
Phase 2
129
Shanghai
2024-05
Not yet open
Fudan University
Phase 1/2
117
Shanghai
2024-04-30
Recruiting
RenJi Hospital
Not applicable
201
Shanghai
2024-04-30
Recruiting
RemeGen Co., Ltd.
Phase 2
79
Shanghai
2024-04-29
Recruiting
Tyligand Pharmaceuticals (Suzhou) Limited
Phase 1/2
440
Hefei, Beijing, Guangzhou, Wuhan, Changsha, Nanchang, Linyi, Shanghai
2024-04-29
Recruiting
Hansoh BioMedical R&D Company
Phase 1
610
Shanghai
2024-04-26
Active, closed
Eli Lilly and Company
Phase 3
450
Beijing, Changsha, Guangzhou, Hangzhou, Jingzhou, Nanchang, Nanning, Shanghai
2024-04-26
Recruiting
A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors
NCT06403735Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor
Qilu Pharmaceutical Co., Ltd.
Phase 1
250
Guangzhou, Harbin, Nanchang, Shanghai, Kunming
2024-04-25
Recruiting
Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma
NCT06445517Advanced Solid Tumors, Relapsed/Refractory B-cell Lymphoma
InSilico Medicine Hong Kong Limited
Phase 1
60
Beijing, Nanchang, Shanghai, Tianjin
2024-04-25
Recruiting
The Efficacy and Safety of HCQ Plus Pred in ANA Positive ITP
NCT06479304Immune Thrombocytopenia With Positive ANA Antibodies
DrugsHydroxychloroquine·Prednisone
Yunfeng Cheng
Not applicable
129
Shanghai
2024-04-24
Recruiting
The Efficacy and Safety of HCQ Plus DEX in ANA Positive ITP
NCT06479317Immune Thrombocytopenia With Positive ANA Antibodies
DrugsHydroxychloroquine·Dexamethasone
Yunfeng Cheng
Not applicable
129
Shanghai
2024-04-24
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 2
180
Shanghai
2024-04-23
Recruiting
Natural Course and Therapeutic Effect of Recurrent Acute Pancreatitis
NCT06355206Cohort Study, Recurrent Acute Pancreatitis
Changhai Hospital
Observational
2,000
Shanghai
2024-04-22
Recruiting
Janssen Research & Development, LLC
Phase 1/2
287
Beijing, Cheng Du Shi, Linyi, Shanghai, Wuhan
2024-04-22
Active, closed
Amgen
Phase 3
111
Beijing, Shenzhen, Wuhan, Suzhou, Changchun, Jinan, Chengdu, Shanghai
2024-04-22
Recruiting
Ruijin Hospital
Phase 2
29
Guangzhou, Shanghai
2024-04-20
Recruiting
Peking Union Medical College Hospital
Observational
3,000
Hefei, Beijing, Nanning, Zhengzhou, Henan, Ningbo, Shanghai, Wuhan
2024-04-19
Active, closed
Jing-yuan Fang, MD, Ph. D
Phase 2
33
Shanghai
2024-04-19
Recruiting
Janssen Research & Development, LLC
Phase 3
641
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanjing, Shanghai
2024-04-18
Recruiting
Fudan University
Not applicable
39
Shanghai
2024-04-17
Recruiting
Huashan Hospital
Not applicable
120
Shanghai
2024-04-17
Recruiting
Ruijin Hospital
Phase 2
16
Shanghai
2024-04-16
Active, closed
A Study of MHB039A for Advanced Solid Tumor
NCT06345482Advanced Solid Tumor
DrugMHB039A
Minghui Pharmaceutical (Hangzhou) Ltd
Phase 1/2
196
Shanghai
2024-04-16
Recruiting
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Not applicable
90
Shanghai
2024-04-15
Recruiting
Shanghai Mental Health Center
Not applicable
62
Shanghai
2024-04-15
Recruiting
Children's Hospital of Fudan University
Observational
60
Shanghai
2024-04-15
Active, closed
Toripalimab Combined With SBRT for NSCLC
NCT06293690Non-small Lung Cancer
DrugsSBRT·Toripalimab
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
40
Shanghai
2024-04-15
Recruiting
A Cohort Study on Early Stages of Heart Failure
NCT06673615Stages of Heart Failure
Shanghai East Hospital
Observational
8,000
Shanghai
2024-04-15
Active, closed
A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
NCT06485219Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL)
DrugPurinostat Mesylate
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 2
50
Shanghai, Chengdu
2024-04-14
Recruiting
Hansoh BioMedical R&D Company
Phase 1
1,048
Shanghai
2024-04-11
Recruiting
Lymph Node Pathologic Grading Strategy
NCT06745830Lung Adenocarcinoma
Fudan University
Observational
2,998
Shanghai
2024-04-10
Recruiting
Huashan Hospital
Phase 4
312
Shanghai
2024-04-10
Recruiting
Fudan University
Phase 3
172
Shanghai
2024-04-09
Not yet open
Huashan Hospital
Not applicable
326
Shanghai
2024-04-08
Recruiting
Ascentage Pharma Group Inc.
Phase 3
344
Bengbu, Guangzhou, Zhanjiang, Zhengzhou, Wuhan, Changsha, Shanghai, Tianjin
2024-04-07
Recruiting
Eye & ENT Hospital of Fudan University
Observational
180
Beijing, Zhengzhou, Changsha, Nanchang, Shanghai, Chengdu
2024-04-06
Recruiting
Société des Produits Nestlé (SPN)
Observational
60
Shanghai
2024-04-06
Recruiting
β-Thalassemia Treatment With KL003 Cell Injection
NCT06280378Transfusion-dependent Beta-Thalassemia
Kanglin Biotechnology (Hangzhou) Co., Ltd.
Phase 1/2
41
Shanghai, Tianjin
2024-04-05
Recruiting
Optimised CD33 (FL-33) CAR T Therapy for Refractory/Relapsed Acute Myeloid Leukaemia
NCT06326021Refractory/Relapsed Acute Myeloid Leukaemia
Beijing GoBroad Hospital
Phase 1
27
Shanghai, Chengdu, Beijing
2024-04-02
Recruiting
Fudan University
Phase 3
1,900
Shanghai
2024-04-02
Recruiting
Changhai Hospital
Not applicable
124
Shanghai
2024-04-02
Recruiting
Shanghai Chest Hospital
Phase 2
54
Shanghai
2024-04-02
Recruiting
Primary Tumor Resection for M1a Stage Lung Cancer
NCT06547710Lung Cancer Metastatic, Surgical Resection
Fudan University
Observational
66
Shanghai
2024-04-01
Not yet open
Baohui Han
Phase 1/2
80
Shanghai
2024-04-01
Active, closed
Shanghai East Hospital
Observational
6
Shanghai
2024-04-01
Recruiting
Fudan University
Phase 2
30
Shanghai
2024-04-01
Active, closed
Shanghai Eye Disease Prevention and Treatment Center
Phase 4
58
Shanghai
2024-04-01
Recruiting
Fudan University
Phase 2
241
Shanghai
2024-04-01
Recruiting
CLL-1 CAR-NK Cells for Relapsed/Refractory AML
NCT06307054Relapsed Adult AML, Refractory AML
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 1
24
Shanghai
2024-04-01
Recruiting
Fudan University
Phase 2
96
Shanghai
2024-04-01
Recruiting
Effect of Belimumab on Antibody Titers in Primary APS Patients
NCT06747312Antiphospholipid Syndrome (APS)
DrugBelimumab
Ruijin Hospital
Phase 2
20
Shanghai
2024-04-01
Recruiting
Children's Hospital of Fudan University
Observational
100
Shanghai
2024-04-01
Not yet open
Cognitive Impairment Cohort Study of the Elderly Population in YuGarden
NCT06325527Alzheimer Disease, Neurodegenerative Diseases, Cognitive Impairment, Mild Cognitive Impairment
Ruijin Hospital
Observational
1,872
Shanghai
2024-04-01
Recruiting
Fudan University
Phase 2
134
Shanghai
2024-04-01
Recruiting
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
30
Shanghai
2024-04-01
Not yet open
Fudan University
Phase 2
25
Anyang, Shanghai
2024-04-01
Recruiting
A Real-world Observational Study of a Mucosal Contouring Method for Radiation-induced Oropharyngeal Mucositis
NCT06308328Radiation-induced Oropharyngeal Mucositis, Swallowing-induced Breakthrough Pain
Nanfang Hospital, Southern Medical University
Observational
718
Guangzhou, Shaoguan, Shenzhen, Zhuhai, Shanghai, Chengdu
2024-04-01
Recruiting
VivaVision Biotech, Inc
Phase 3
700
Shanghai
2024-04-01
Recruiting
Wearable Devices Faciliate the Management of AMI Patients
NCT06995495Acute Myocardial Infarction
RenJi Hospital
Observational
400
Shanghai
2024-04-01
Not yet open
Shen Lei
Phase 4
156
Shanghai
2024-04
Recruiting
Bausch & Lomb Incorporated
Not applicable
418
Beijing, Dongcheng, Xiamen, Haikou, Wuhan, Shanghai, Taiyuan, Shenzhen
2024-03-29
Active, closed
Takeda
Phase 2
213
Chongqing, Guangzhou, Changsha, Changzhou, Shenyang, Shanghai, Chengdu, Hangzhou
2024-03-29
By invitation
Xijing Hospital
Not applicable
320
Shanghai, Xi'an
2024-03-28
Recruiting
Changhai Hospital
Not applicable
9
Shanghai
2024-03-28
Recruiting
Fudan University
Phase 2
192
Shanghai
2024-03-28
Active, closed
Qiyu Bo
Observational
300
Shanghai
2024-03-26
Recruiting
Medtecx Co Ltd.
Not applicable
126
Hefei, Beijing, Wuhan, Nanjing, Nanchang, Xi'an, Shanghai, Tianjin
2024-03-26
Recruiting
Shanghai Chest Hospital
Not applicable
216
Shanghai
2024-03-24
Recruiting
Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies
NCT06316427T-cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia, T-cell Malignancies
Beijing GoBroad Hospital
Phase 1/2
80
Beijing, Shanghai, Chengdu
2024-03-22
Recruiting
RenJi Hospital
Not applicable
192
Shanghai
2024-03-21
Recruiting
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
NCT06249438Systemic Lupus Erythematosus (SLE), Immune-mediated Necrotizing Myopathy (IMNM), Neuromyelitis Optica Spectrum Disorders (NMOSD), Multiple Sclerosis (MS)
DrugC-CAR168
RenJi Hospital
Phase 1
30
Shanghai
2024-03-20
Active, closed
Intuitive Surgical
Not applicable
354
Shanghai, Chengdu
2024-03-20
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
80
Zhengzhou, Nanjing, Suzhou, Shanghai, Wenzhou
2024-03-19
Recruiting
a Feasibility Study of iHD-SRT for BM
NCT06231186Brain Metastases, Adult, Stereotactic Radiotherapy
Ruijin Hospital
Not applicable
35
Shanghai
2024-03-15
Active, closed
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3
506
Shanghai
2024-03-15
Recruiting
Anhui Provincial Hospital
Phase 3
198
Hefei, Beijing, Zhengzhou, Wuhan, Shanghai, Hangzhou
2024-03-15
Recruiting
AstraZeneca
Phase 3
100
Beijing, Changchun, Changsha, Dongguan, Nanjing, Shanghai, Suzhou, Wenzhou
2024-03-14
Recruiting
Fudan University
Observational
300
Shanghai
2024-03-14
Recruiting
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 3
442
Shanghai
2024-03-13
Recruiting
Shanghai East Hospital
Not applicable
3
Shanghai
2024-03-13
Recruiting
IVUS CHIP China Registry
NCT06274645Complex Higher Risk Indicated Patients Undergoing PCI
Shanghai Zhongshan Hospital
Observational
2,020
Shanghai
2024-03-12
Recruiting
Shanghai 6th People's Hospital
Phase 2
20
Shanghai
2024-03-12
Recruiting
Prediction and Intervention Effect of Rehabilitation Status for Severe Mental Disorder Patients Based on Multimodal Analysis and AI Agents
NCT06904079Severe Mental Disorder, Schizophrenia, Schizoaffective Disorder, Paranoid Psychosis
Shanghai Mental Health Center
Not applicable
82
Shanghai
2024-03-12
Recruiting
Fudan University
Observational
500
Shanghai
2024-03-12
Recruiting
Novartis Pharmaceuticals
Phase 3
450
Beijing, Guangzhou, Shanghai
2024-03-12
By invitation
Shanghai Eye Disease Prevention and Treatment Center
Not applicable
20
Shanghai
2024-03-11
Recruiting
Fudan University
Phase 3
722
Shanghai
2024-03-10
Recruiting
Shanghai Cell Therapy Group Co.,Ltd
Early Phase 1
20
Shanghai
2024-03-07
Recruiting
Xizang Haisco Pharmaceutical Co., Ltd
Phase 1/2
243
Shanghai
2024-03-07
Active, closed
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
NCT06238479Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
Eli Lilly and Company
Phase 1
490
Beijing, Changsha, Shanghai
2024-03-05
Recruiting
Suzhou Genhouse Bio Co., Ltd.
Phase 1/2
94
Hefei, Zhengzhou, Changsha, Nanjing, Shanghai, Linhai
2024-03-05
Recruiting
Fudan University
Phase 2
210
Fuzhou, Nantong, Shanghai, Hangzhou, Ningbo
2024-03-04
Recruiting
RenJi Hospital
Not applicable
80
Shanghai
2024-03-04
Active, closed
Clinical Study of Safety and Efficacy of Enhanced PSMA CAR- T in Refractory CRPC
NCT06228404Metastatic Castration-resistant Prostate Cancer, Castration-resistant Prostate Cancer
Shanghai Changzheng Hospital
Early Phase 1
18
Shanghai
2024-03-03
Recruiting
A-eyedrops on Ocular Alignment and Binocular Vision
NCT05379855Exotropia, Exophoria, Myopia
DrugAtropine eye
Eye & ENT Hospital of Fudan University
Not applicable
339
Shanghai
2024-03-02
Recruiting
RenJi Hospital
Not applicable
80
Shanghai
2024-03-01
Recruiting
STICH3C Cardiac Magnetic Resonance Observational Study
NCT07133984Ischemic Left Ventricle Systolic Dysfunction, Multivessel Coronary Artery Disease
Weill Medical College of Cornell University
Observational
230
Shanghai
2024-03-01
By invitation
Shanghai Eye Disease Prevention and Treatment Center
Not applicable
252
Shanghai
2024-03-01
Active, closed
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3
130
Shanghai
2024-03-01
Recruiting
Fudan University
Phase 2
30
Shanghai
2024-03-01
Recruiting
Hongmeng Yu
Phase 2
25
Shanghai
2024-03-01
Active, closed
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
98
Hefei, Shanghai
2024-03-01
Active, closed
Upfront Immune Checkpoint Inhibitors With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma
NCT06279403Immune Checkpoint Inhibitors, Cytoreductive Nephrectomy, Clear Cell Renal Cell Cancer (ccRCC)
DrugsAxitinib·Toripalimab
RenJi Hospital
Phase 2
21
Shanghai
2024-03-01
Recruiting
Micro-encapsulated Hepatocyte Intraperitoneal Transplantation in Liver Failure Adults
NCT05727722Acute-On-Chronic Liver Failure, Chronic Liver Failure
RenJi Hospital
Phase 1
10
Shanghai
2024-03-01
Recruiting
Multicenter Prospective Cohort Study of Twin Maternal-Child Dyads in China
NCT06414655Twin Pregnancy, Antepartum Condition or Complication, Twin to Twin Transfusion as Antepartum Condition, Pre-Term, Pre-Eclampsia
Peking University Third Hospital
Observational
2,000
Hefei, Beijing, Chongqing, Guangzhou, Shenyang, Jinan, Shanghai, Tianjin
2024-03-01
Recruiting
RenJi Hospital
Observational
120
Shanghai
2024-03-01
Active, closed
Anhui Provincial Hospital
Phase 3
198
Hefei, Beijing, Zhengzhou, Wuhan, Shanghai, Hangzhou
2024-03-01
By invitation
Intervention and Effect of Sleep Pattern on Cardio-cerebrovascular Disease
NCT06294964Cardiovascular Diseases, Non-Communicable Chronic Diseases
RenJi Hospital
Not applicable
12,800
Shanghai
2024-03-01
Recruiting
Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma
NCT06228963MALT Lymphoma of Stomach, Helicobacter Pylori Infection
Fudan University
Phase 2
160
Shanghai
2024-03
Active, closed
Sanofi
Phase 3
464
Changchun, Chongqing, Guangzhou, Hangzhou, Nanyang, Ningbo, Shanghai, Shenyang
2024-02-29
Recruiting
Shanghai Huaota Biopharmaceutical Co., Ltd.
Phase 2
33
Beijing, Shanghai
2024-02-29
Recruiting
Fudan University
Observational
80
Shanghai
2024-02-29
Recruiting
Novartis Pharmaceuticals
Phase 3
50
Nanjing, Beijing, Shanghai
2024-02-28
Active, closed
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
537
Shanghai
2024-02-28
Recruiting
HC Biopharma Inc.
Phase 1
76
Shanghai
2024-02-27
Recruiting
Children's Hospital of Fudan University
Early Phase 1
6
Shanghai
2024-02-20
Recruiting
Neoadjuvant Immunochemotherapy for LAOSCC
NCT06258811Oral Squamous Cell Carcinoma, Locally Advanced Head and Neck Carcinoma
Lai-ping Zhong
Phase 3
134
Shanghai
2024-02-20
Active, closed
AbbVie
Observational
1,200
Beijing, Chongqing, Guangzhou, Nanjing, Shanghai, Chengdu, Jinhua
2024-02-19
Recruiting
Suzhou Huhu Health & Technology Inc.
Observational
258
Shanghai
2024-02-18
Recruiting
Suzhou Huhu Health & Technology Inc.
Observational
1,197
Shanghai
2024-02-18
Recruiting
Tongji University
Phase 2
25
Shanghai
2024-02-17
Not yet open
Ruijin Hospital
Phase 3
142
Shanghai
2024-02-15
Recruiting
Carotid Atherosclerosis in Predicting Coronary Artery Disease
NCT06253962Carotid Atherosclerosis, Coronary Atheroscleroses
Shanghai Zhongshan Hospital
Observational
1,000
Shanghai
2024-02-10
Active, closed
Boehringer Ingelheim
Phase 3
428
Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Shanghai, Taizhou
2024-02-09
Active, closed
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
104
Chongqing, Fuzhou, Guiyang, Harbin, Changsha, Shenyang, Shanghai
2024-02-05
Not yet open
Fudan University
Phase 3
524
Shanghai
2024-02-05
Recruiting
Qing XIe
Not applicable
2,016
Shanghai
2024-02-04
Recruiting
Sichuan Huiyu Pharmaceutical Co., Ltd
Phase 1/2
257
Fuzhou, Changsha, Shenyang, Jinan, Shanghai, Chengdu
2024-02-04
Recruiting
A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AML
NCT06329999Recurrent Adult Acute Myeloid Leukemia, Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia
Ruijin Hospital
Not applicable
78
Shanghai
2024-02-03
Recruiting
Study SC-101 in Subjects With Advanced Malignancies
NCT06220838Advanced Solid Tumor
Tianjin ConjuStar Biologics Co., Ltd.
Phase 1
100
Beijing, Changsha, Nanjing, Shanghai, Tianjin
2024-02-02
Recruiting
Toripalimab Combined With Definitive CCRT for LACC Patients
NCT06256224Cervical Cancer, Chemoradiotherapy, Immunotherapy
DrugToripalimab
Ruijin Hospital
Not applicable
150
Shanghai
2024-02-02
Recruiting
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
58
Shanghai
2024-02-02
Recruiting
Huashan Hospital
Observational
500
Shanghai
2024-02-01
Recruiting
Changhai Hospital
Not applicable
428
Shanghai
2024-02-01
Active, closed
Ruijin Hospital
Phase 4
80
Shanghai
2024-02-01
Recruiting
Shanghai Jiao Tong University School of Medicine
Phase 2
60
Shanghai
2024-02-01
By invitation
The Novel Special Light for Endotracheal/Bronchial Lesions.
NCT07036614Tracheal Disease, Bronchial Disease
Shanghai Chest Hospital
Observational
400
Shanghai
2024-01-31
Active, closed
Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC
NCT05894889Stage IIIB(N2) Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer
DrugsNab-paclitaxel·Pemetrexed·Carboplatin·Pembrolizumab
Peking University
Phase 2
70
Beijing, Shanghai
2024-01-30
Recruiting
Application of EndoScell Intraoperative Cellular Probing Technology for Early-Stage Breast Cancer
NCT06911528Breast Cancer, Sentinel Lymph Node, Frozen Section, Cytology
Fudan University
Not applicable
709
Shanghai
2024-01-30
Recruiting
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Not applicable
9
Shanghai
2024-01-26
Recruiting
Clinical Study of Carbon Ion Radiotherapy Combined With Chemotherapy for Thymic Epithelial Tumors
NCT06186726Carbon Ion Radiotherapy, Thymoma, Thymic Carcinoma, Radiotherapy, Chemotherapy
Jian Chen
Phase 2
48
Shanghai
2024-01-26
Active, closed
Innostellar Biotherapeutics Co.,Ltd
Phase 2
50
Hefei, Hangzhou, Beijing, Chengdu, Guangzhou, Shanghai, Taiyuan, Tianjin
2024-01-24
Recruiting
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
NCT06137144Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL)
DrugsAZD3470·Keytruda·Pembrolizumab
AstraZeneca
Phase 1/2
161
Beijing, Guangzhou, Shanghai
2024-01-23
Recruiting
Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary Involvement
NCT06111612Acute Myeloid Leukemia, Myelodysplastic Neoplasm, Chronic Myelomonocytic Leukemia, Myeloid Sarcoma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Observational
50
Shanghai
2024-01-20
Active, closed
Pfizer
Phase 3
394
Guangzhou, Wuhan, Shenyang, Shanghai, Kunming
2024-01-19
Active, closed
Janssen Research & Development, LLC
Phase 3
112
Beijing, Changzhou, Hangzhou, Shanghai, Shenyang, Zhengzhou
2024-01-19
Recruiting
AstraZeneca
Phase 1/2
334
Beijing, Chengdu, Shanghai, Wuhan
2024-01-18
Recruiting
Eye & ENT Hospital of Fudan University
Phase 2
32
Shanghai
2024-01-18
Active, closed
Takeda
Observational
154
Shanghai
2024-01-17
Recruiting
Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma
NCT06211790Kidney Cancer, Renal Cell Carcinoma, Renal Clear Cell Carcinoma
Fudan University
Phase 2
66
Shanghai
2024-01-16
Recruiting
Fudan University
Phase 1/2
56
Shanghai
2024-01-15
Recruiting
Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)
NCT06141369Adrenal Cortical Carcinoma, Medullary Thyroid Cancer, Thymic Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Tumor
Shanghai Jiao Tong University School of Medicine
Not applicable
21
Shanghai
2024-01-13
Recruiting
Shanghai Synvida Biotechnology Co.,Ltd.
Early Phase 1
53
Shanghai
2024-01-12
Recruiting
Fudan University
Phase 2
30
Shanghai
2024-01-10
Recruiting
Children's Hospital of Fudan University
Phase 4
10
Shanghai
2024-01-10
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
360
Shanghai
2024-01-09
Recruiting
Chengdu New Radiomedicine Technology Co. LTD.
Phase 1
58
Zhengzhou, Suzhou, Shanghai, Chongqing, Tianjin
2024-01-09
Active, closed
Pfizer
Phase 2
333
Wuhan, Changsha, Shanghai
2024-01-09
Recruiting
Shanghai Changzheng Hospital
Not applicable
480
Shanghai
2024-01-08
By invitation
Efficacy of Vitamin B1 in Familial Adenomatous Polyposis Patients.
NCT06649825Familial Adenomatous Polyposis (FAP)
Shanghai Zhongshan Hospital
Not applicable
10
Shanghai
2024-01-08
Recruiting
Children's Hospital of Fudan University
Not applicable
110
Shanghai
2024-01-08
Recruiting
Fudan University
Phase 4
37
Shanghai
2024-01-05
Recruiting
Shanghai BDgene Co., Ltd.
Phase 1
9
Guangzhou, Nanning, Shanghai
2024-01-05
Recruiting
Shanghai IxCell Biotechnology Co., LTD
Phase 3
398
Shanghai
2024-01-05
Recruiting
Huashan Hospital
Phase 2
75
Shanghai
2024-01-05
Recruiting
Shanghai Chest Hospital
Not applicable
110
Shanghai
2024-01-04
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
124
Beijing, Changsha, Chengdu, Nanchang, Qingdao, Shanghai, Shenzhen
2024-01-03
Recruiting
Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors
NCT06950086HR-positive, HER2-negative Advanced Breast Cancer
DrugTYK-00540
TYK Medicines, Inc
Phase 1/2
180
Shanghai
2024-01-02
Active, closed
Ultrasound Assessment of Isolated Distal Deep Vein Thrombosis
NCT06596941Iddvt, Pulmonary Embolism (PE)
Ruijin Hospital
Observational
800
Shanghai
2024-01-01
Not yet open
Shanghai Chest Hospital
Not applicable
300
Shanghai
2024-01-01
Recruiting
Fudan University
Phase 1/2
50
Shanghai
2024-01-01
Recruiting
Bile Omics for Diagnosing Indeterminate Biliary Strictures
NCT07007832Cholangiocarcinoma, Gallbladder Cancer and Extrahepatic Cholangiocarcinoma, Pancreatic Cancer, Bile Duct Strictures of Unknown Origin
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Observational
260
Shanghai
2024-01-01
Recruiting
A Prospective Study on Esophagogastrostomy by an Innovative Surgical Technique
NCT06300879Gastric Cancer, Adenocarcinoma of Esophagogastric Junction
Huashan Hospital
Not applicable
30
Shanghai
2024-01-01
Recruiting
RenJi Hospital
Observational
180
Shanghai
2024-01-01
Recruiting
Chengdu JOYO pharma Co., Ltd.
Phase 1
75
Shanghai
2024-01-01
Recruiting
A New Cardiac Rehabilitation Treatment in the Application of Ischemic Heart Disease
NCT06681506Ischemic Heart Disease, Cardiac Rehabilitation
Shanghai 10th People's Hospital
Not applicable
100
Shanghai
2024-01-01
Recruiting
Fudan University
Observational
166
Shanghai
2024-01-01
Recruiting
Shanghai Chest Hospital
Not applicable
100
Zhengzhou, Beijing, Chengdu, Linyi, Nanchang, Shanghai, Shijiazhuang, Zhejiang
2024-01-01
Active, closed
RenJi Hospital
Observational
462
Shanghai
2024-01-01
Recruiting
Fudan University
Phase 2
53
Shanghai
2024-01-01
Recruiting
Beth Israel Deaconess Medical Center
Not applicable
300
Shanghai
2024-01-01
Not yet open
Changhai Hospital
Not applicable
30
Shanghai
2024-01-01
Not yet open
Shanghai Zhongshan Hospital
Phase 2
19
Shanghai
2024-01-01
Active, closed
Quick Yielding Modified Short-Distance Fenestration Technique for the Treatment of Complex Aortic Arch Diseases: a Multicenter Single-Arm Objective Performance Criteria Trial(QYM-Tech Study)
NCT06639243Thoracic Aortic Dissection, Thoracic Aortic Aneurysm (true Aneurysm), Thoracic Pseudoaneurysm, Penetrating Aortic Ulcer
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Not applicable
87
Shanghai
2024-01-01
Not yet open
Fudan University
Early Phase 1
30
Shanghai
2024-01
Not yet open
Shanghai Changzheng Hospital
Not applicable
132
Shanghai
2024-01
Recruiting
Children's Hospital of Fudan University
Observational
2,000
Shanghai
2023-12-31
Active, closed
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Not applicable
635
Shanghai
2023-12-29
Recruiting
Bristol-Myers Squibb
Phase 1/2
460
Beijing, Guangzhou, Zhengzhou, Suzhou, Nanchang, Shenyang, Qingdao, Shanghai
2023-12-29
Recruiting
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 3
432
Shanghai
2023-12-29
Recruiting
Fudan University
Phase 2
1,100
Shanghai
2023-12-28
By invitation
Guangzhou JOYO Pharma Co., Ltd
Phase 2
120
Shanghai
2023-12-27
Recruiting
RenJi Hospital
Not applicable
1,200
Nanjing, Nanchang, Jinan, Shanghai, Xi’an, Tianjin, Hangzhou
2023-12-27
Recruiting
Gracell Biotechnologies (Shanghai) Co., Ltd.
Phase 1/2
110
Beijing, Hangzhou, Jinan, Shanghai, Shenyang, Wenzhou, Wuhan, Xi'an
2023-12-26
Recruiting
Qilu Pharmaceutical Co., Ltd.
Phase 3
270
Bengbu, Bozhou, Hefei, Beijing, Fuzhou, Dalian, Shanghai, Changzhi
2023-12-25
Recruiting
RenJi Hospital
Not applicable
120
Shanghai
2023-12-24
Active, closed
nthalmic Pty Ltd
Not applicable
210
Tianjin, Shanghai
2023-12-22
Active, closed
Fudan University
Not applicable
50
Shanghai
2023-12-21
Active, closed
Suzhou Alphamab Co., Ltd.
Phase 2
241
Shanghai
2023-12-20
Recruiting
Ruijin Hospital
Early Phase 1
34
Shanghai
2023-12-20
Not yet open
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
160
Shanghai
2023-12-20
Active, closed
AbbVie
Phase 3
614
Beijing, Guangzhou, Wuhan, Xi'an, Jinan, Shanghai, Chengdu, Tianjin
2023-12-19
Recruiting
Fudan University
Observational
168
Guangzhou, Shenyang, Shanghai
2023-12-18
Recruiting
Fudan University
Observational
276
Shanghai
2023-12-18
Active, closed
Fudan University
Phase 2
20
Shanghai
2023-12-18
Recruiting
Shanghai Pulmonary Hospital, Shanghai, China
Observational
2,000
Shanghai
2023-12-16
Recruiting
Shanghai Chest Hospital
Observational
200
Shanghai
2023-12-15
Not yet open
Fudan University
Phase 2
182
Shanghai
2023-12-15
Recruiting
Shanghai Jiao Tong University School of Medicine
Observational
2,042
Shanghai
2023-12-15
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
58
Shanghai
2023-12-12
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
52
Shanghai
2023-12-11
Recruiting
Shanghai Tongji Hospital, Tongji University School of Medicine
Early Phase 1
12
Shanghai
2023-12-11
Recruiting
Eikon Therapeutics
Phase 1/2
156
Guangzhou, Shijiazhuang, Jinan, Hangzhou, Chongqing, Fuzhou, Shanghai
2023-12-11
Recruiting
AbbVie
Phase 3
110
Beijing, Guangzhou, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai
2023-12-11
Recruiting
Jian Chen
Phase 2
77
Shanghai
2023-12-07
Recruiting
Ruijin Hospital
Not applicable
89
Shanghai
2023-12-06
Recruiting
Fudan University
Phase 2
65
Shanghai
2023-12-05
Recruiting
Shanghai Zhongshan Hospital
Phase 2
26
Shanghai
2023-12-01
By invitation
Shanghai Jiao Tong University School of Medicine
Observational
1,000
Shanghai
2023-12-01
Recruiting
Changchun GeneScience Pharmaceutical Co., Ltd.
Not applicable
290
Beijing, Chongqing, Changsha, Nanjing, Suzhou, Shanghai, Xi’an, Chengdu
2023-12-01
Recruiting
Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency
NCT06095141Pancreatic Adenocarcinoma, Homologous Recombination Deficiency
DrugCisplatin
Fudan University
Phase 2/3
30
Shanghai
2023-12-01
Recruiting
Shanghai Mental Health Center
Not applicable
138
Shanghai
2023-12-01
Not yet open
RenJi Hospital
Not applicable
60
Shanghai
2023-12-01
Recruiting
Shanghai Pulmonary Hospital, Shanghai, China
Observational
250
Shanghai
2023-12-01
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
1,384
Beijing, Shanghai, Chengdu
2023-12-01
Recruiting
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Not applicable
260
Shanghai
2023-12-01
Recruiting
Fudan University
Phase 3
266
Shanghai
2023-12-01
Not yet open
RenJi Hospital
Observational
40
Shanghai
2023-12-01
Recruiting
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
NCT06120283Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer
DrugsBGB-43395·Elacestrant·Letrozole·Fulvestrant
BeOne Medicines
Phase 1
433
Beijing, Fuzhou, Guangzhou, Harbin, Nanchang, Shenyang, Shanghai
2023-12-01
Recruiting
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 3
400
Guangzhou, Shanghai, Anyang, Baoding, Beijing, Changchun, Changde, Changsha
2023-12-01
Recruiting
Shanghai Jiao Tong University School of Medicine
Phase 3
120
Shanghai
2023-12-01
Not yet open
Shanghai Chest Hospital
Phase 2
36
Shanghai
2023-12
Not yet open
Huashan Hospital
Early Phase 1
6
Shanghai
2023-12
Not yet open
YiHui Guan
Not applicable
15
Shanghai
2023-12
Recruiting
Ruijin Hospital
Phase 2
30
Beijing, Guangzhou, Henan, Shanghai, Wuhan
2023-11-30
Active, closed
argenx
Observational
413
Changsha, Nanchang, Shanghai
2023-11-29
Recruiting
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1
170
Shanghai
2023-11-28
Recruiting
RemeGen Co., Ltd.
Phase 2
40
Shanghai
2023-11-28
By invitation
Shanghai Zhongshan Hospital
Observational
28
Shanghai
2023-11-28
Recruiting
Zhejiang Doer Biologics Co., Ltd.
Phase 1
216
Shanghai
2023-11-27
Recruiting
Huashan Hospital
Observational
160
Shanghai
2023-11-26
Recruiting
Prognosis of Patients With Upper Tract Urothelial Carcinoma Receiving Kidney-sparing Therapy
NCT06204406Upper Tract Urothelial Carcinoma Receiving Kidney-sparing Therapy
RenJi Hospital
Observational
106
Shanghai
2023-11-23
Recruiting
Fudan University
Not applicable
58
Shanghai
2023-11-20
Recruiting
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
NCT06131840Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma
DrugsLeucovorin·Adrucil·Oxaliplatin·Bevacizumab
Seagen, a wholly owned subsidiary of Pfizer
Phase 1
914
Guangzhou, Jinan, Shanghai
2023-11-20
Active, closed
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
1,615
Shanghai, Tianjin
2023-11-20
Recruiting
Shenyang Sunshine Pharmaceutical Co., LTD.
Phase 1
60
Shanghai
2023-11-20
Recruiting
Shanghai Pulmonary Hospital, Shanghai, China
Not applicable
304
Shanghai, Zhejiang
2023-11-20
Recruiting
RenJi Hospital
Phase 2
22
Nanjing, Xi'an, Shanghai, Chengdu, Tianjin
2023-11-16
By invitation
Children's Hospital of Fudan University
Observational
1,000
Yiyang, Nantong, Shanghai, Baoji, Quzhou
2023-11-16
Recruiting
Ruijin Hospital
Phase 2
23
Shanghai
2023-11-15
Recruiting
Takeda
Phase 3
80
Beijing, Guangzhou, Shenzhen, Shanghai, Tianjin
2023-11-13
Active, closed
Novartis Pharmaceuticals
Phase 1
28
Shanghai
2023-11-13
Recruiting
RenJi Hospital
Not applicable
840
Shanghai
2023-11-11
Active, closed
AstraZeneca
Phase 3
314
Beijing, Guangzhou, Hangzhou, Lanzhou, Shanghai, Tianjin
2023-11-08
Recruiting
Lu jin ，MD
Phase 2
10
Shanghai
2023-11-06
Recruiting
Oral Prednisone in Treating LCH of Bone in Childhood and Adolescence
NCT06078969Langerhans Cell Histiocytosis of Bone
DrugPrednisone
Shanghai Changzheng Hospital
Phase 2
118
Shanghai
2023-11-04
Recruiting
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
25
Shanghai
2023-11-04
Active, closed
Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL
NCT06093841Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma, Mediastinal B-Cell Diffuse Large Cell Lymphoma
DrugsRelmacabtagene Autoleucel·Relma-cel·Fludarabine·Cyclophosphamide
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 2
46
Guangzhou, Zhengzhou, Changsha, Suzhou, Jinan, Shanghai, Tianjin, Hangzhou
2023-11-03
Recruiting
Shanghai Jiao Tong University School of Medicine
Phase 2
120
Shanghai
2023-11-01
Recruiting
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 2
50
Shanghai
2023-11-01
Recruiting
Surveillance for Multifocal GGNs
NCT06097910Lung Ground-glass Opacities, Active Surveillance
Fudan University
Observational
370
Shanghai
2023-11-01
Active, closed
PET-CT Predicting Lymph Nodes Metastasis
NCT05970913Non Small Cell Lung Cancer, Lymph Node Metastasis, Positron Emission Tomography
Fudan University
Observational
280
Shanghai
2023-11-01
Recruiting
Mao Jianhua
Phase 3
140
Wuhan, Nanjing, Kunming, Hangzhou, Ningbo, Wenzhou, Beijing, Shanghai
2023-11-01
Recruiting
Cohort in Qianwan New District, Ningbo
NCT06387875Cardiovascular Diseases, Stroke, Non-Communicable Chronic Diseases
RenJi Hospital
Observational
30,000
Shanghai
2023-11-01
Recruiting
HRYZ-T101 Injection for HPV18 Positive Solid Tumor
NCT05952947Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Carcinoma of Vagina, Carcinoma of Penis
DrugsFludarabine·Cyclophosphamide
HRYZ Biotech Co.
Phase 1
32
Shanghai
2023-11-01
Recruiting
Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer
NCT06017284Pancreatic Cancer Stage IV, Chemotherapy-induced Nausea and Vomiting
DrugsThalidomide·Nab-paclitaxel·Gemcitabine
Fudan University
Phase 3
100
Shanghai
2023-11-01
Not yet open
Wedge Resection for Ground-glass Opacity-featured Lung Cancer (ECTOP-1020)
NCT06102161Lung Cancer, Wedge Resection, Ground-glass Opacity
Fudan University
Phase 3
286
Shanghai
2023-11
Recruiting
Shanghai Zhongshan Hospital
Not applicable
428
Shanghai
2023-10-31
Active, closed
Shouyao Holdings (Beijing) Co. LTD
Phase 3
120
Shanghai
2023-10-31
Not yet open
Selinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCL
NCT06062641Relapsed or Refractory B-cell Lymphoma
Ruijin Hospital
Phase 2
50
Shanghai
2023-10-30
Recruiting
Geneplus-Beijing Co. Ltd.
Observational
60
Beijing, Shanghai
2023-10-30
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
95
Shanghai
2023-10-30
Recruiting
OriCell Therapeutics Co., Ltd.
Phase 1/2
83
Hangzhou, Beijing, Nanjing, Shanghai, Wuhan
2023-10-26
Recruiting
Shanghai Yuyao Biotech Co., Ltd.
Phase 1
96
Shanghai
2023-10-26
Recruiting
Shanghai Pulmonary Hospital, Shanghai, China
Observational
377
Shanghai
2023-10-25
Active, closed
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
NCT05952037Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory
DrugsSonrotoclax·Zanubrutinib
BeOne Medicines
Phase 2
114
Xiamen, Guangzhou, Zhengzhou, Wuhan, Yancheng, Shenyang, Qingdao, Shanghai
2023-10-23
Recruiting
Hoffmann-La Roche
Phase 3
182
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanning, Shanghai
2023-10-22
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
186
Shanghai
2023-10-20
Recruiting
Shanghai Jiao Tong University School of Medicine
Phase 3
222
Fuzhou, Xiamen, Nanning, Nanjin, Suzhou, Shanghai, Kunming
2023-10-19
Recruiting
Huashan Hospital
Phase 2
50
Shanghai
2023-10-18
Recruiting
Abbisko Therapeutics Co, Ltd
Phase 2
82
Shanghai, Chengdu, Ha’erbin, Wuhan
2023-10-17
Recruiting
De-escalation Radiation Strategy After NAC in Combination With ICI in LAHNSCC
NCT06572514Locally Advanced Head and Neck Squamous Cell Carcinoma
Ruijin Hospital
Phase 1/2
20
Shanghai
2023-10-17
Recruiting
Neuracle Medical Technology(Shanghai) Co.,Ltd.
Not applicable
9
Beijing, Shanghai
2023-10-17
By invitation
Identification and Functional Study of Novel Biomarkers for Cardiovascular Diseases
NCT06690684Angiocardiography, Heart Failure, Ischemic Heart Disease, Acute Myocardial Infarction (AMI)
Ya-Wei Xu
Observational
300
Shanghai
2023-10-17
Active, closed
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 2
72
Shanghai
2023-10-17
Recruiting
Shanghai Mental Health Center
Not applicable
18
Shanghai
2023-10-16
Recruiting
Cohort of Twin Pregnancy and the Offspring
NCT05727085Twin Pregnancy
Fudan University
Observational
1,000
Shanghai
2023-10-15
Recruiting
Preoperative Serum FGF19 in the Prognosis of Biliary Atresia
NCT05848310Biliary Atresia, Prognosis
Children's Hospital of Fudan University
Observational
200
Shanghai
2023-10-15
Recruiting
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT05882058Small Cell Lung Carcinoma, Neuroendocrine Neoplasms, Extra-pulmonary Neuroendocrine Carcinoma
DrugObrixtamig
Boehringer Ingelheim
Phase 2
204
Chengdu, Hangzhou, Jinan, Nanchang, Shanghai
2023-10-13
Recruiting
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Observational
132
Shanghai
2023-10-11
Recruiting
Hangzhou Broncus Medical Co., Ltd.
Not applicable
110
Shanghai
2023-10-11
Active, closed
Acute Health Effects of Low Temperature Exposure
NCT06076629Cardiovascular System, Respiratory System, Cognitive Function
Fudan University
Not applicable
50
Shanghai
2023-10-10
Recruiting
Sanofi
Phase 3
180
Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Shanghai, Wuxi
2023-10-10
Recruiting
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Not applicable
12
Shanghai
2023-10-08
Recruiting
CARsgen Therapeutics Co., Ltd.
Phase 1
30
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guanzhou, Hangzhou, Shanghai
2023-10-08
By invitation
Biogen
Phase 3
306
Beijing, Shenzhen, Dongguan, Guangzhou, Changsha, Nanjing, Shanghai, Kunming
2023-10-03
Recruiting
AbbVie
Phase 3
90
Chongqing, Suzhou, Xi'an, Shanghai, Hangzhou
2023-10-02
Recruiting
RenJi Hospital
Observational
480
Shanghai
2023-10-01
Recruiting
Real-World Study of DLBCL With Different Genetic Subtypes
NCT06026488DLBCL - Diffuse Large B Cell Lymphoma, Lymphoma
Ruijin Hospital
Observational
10,000
Shanghai
2023-10-01
Recruiting
Shanghai Chest Hospital
Observational
250
Shanghai
2023-10-01
Recruiting
Fudan University
Not applicable
160
Shanghai
2023-10-01
Recruiting
Amplification of Autologous Epidermal Cells to Repair Large Area Deep Wounds
NCT05882110Autologous Epidermal Cell Transplantation
Yicheng Ma
Not applicable
100
Shanghai
2023-10-01
Recruiting
Fudan University
Observational
50
Shanghai
2023-10-01
Not yet open
Fudan University
Phase 4
384
Shijiazhuang, Zhengzhou, Changsha, Nantong, Yangzhou, Shanghai, Hangzhou, Jiaxin
2023-10
Recruiting
Tumor Vaccines for Solid Tumors
NCT06102837Glioma, Solid Tumor
DrugTumor vaccine
Huashan Hospital
Observational
340
Shanghai
2023-10
Recruiting
Shanghai East Hospital
Phase 1
24
Shanghai
2023-10
Recruiting
Chinese Community Sample of Hierarchical Model of Psychopathology
NCT06105970Mental Health Issue, Adverse Childhood Experience
Shanghai Mental Health Center
Observational
4,000
Shanghai
2023-09-26
Active, closed
A Study of ADRX-0706 in Select Advanced Solid Tumors
NCT06036121Solid Tumors, Triple Negative Breast Cancer (TNBC), Urothelial Cancer, Cervical Cancer
Adcentrx Therapeutics
Phase 1
144
Beijing, Fujian, Guangzhou, Hunan, Jinan, Shanghai, Wuhan
2023-09-26
Recruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 2
62
Shanghai
2023-09-25
Active, closed
A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD
NCT05972473Neovascular Age-related Macular Degeneration
DrugIBI302
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3
600
Shanghai
2023-09-21
Recruiting
PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor
NCT05801237Locally Advanced/Metastatic Solid Tumors
Shanghai HyaMab Biotech Co.,Ltd.
Phase 1/2
120
Shanghai
2023-09-21
Active, closed
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
165
Beijing, Lanzhou, Tangshan, Shanghai, Tianjin
2023-09-21
Recruiting
BeOne Medicines
Phase 1
337
Hefei, Harbin, Wuhan, Shenyang, Jining, Yantai, Shanghai, Chengdu
2023-09-21
Recruiting
Recurrent High Grade Glioma Treated by LITT
NCT06161610Recurrent High Grade Glioma
Beijing Tiantan Hospital
Not applicable
135
Beijing, Guangzhou, Zhengzhou, Wuhan, Changchun, Shenyang, Jinan, Shanghai
2023-09-19
Recruiting
Shanghai Zhongshan Hospital
Phase 2
40
Shanghai
2023-09-19
Recruiting
D3 Bio (Wuxi) Co., Ltd
Phase 1
128
Harbin, Shanghai, Hangzhou
2023-09-19
Recruiting
Shanghai 10th People's Hospital
Observational
3,000
Shanghai
2023-09-18
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
NCT05878717Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
DrugBelimumab
GlaxoSmithKline
Phase 2/3
300
Beijing, Changchun, Chengdu, Luzhou, Mianyang, Nanjing, Nanning, Shanghai
2023-09-13
Active, closed
Efficacy and Safety of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations
NCT07054632Inherited Retinal Dystrophy Associated With RPE65 Mutations
Innostellar Biotherapeutics Co.,Ltd
Phase 3
30
Guangzhou, Chongqing, Shanghai, Tianjin
2023-09-13
Recruiting
Fudan University
Phase 2
25
Shanghai
2023-09-13
By invitation
argenx
Phase 3
240
Guangzhou, Nanjing, Beijing, Chengdu, Shanghai, Shenyang, Zhengzhou
2023-09-12
Active, closed
Innostellar Biotherapeutics Co.,Ltd
Phase 1/2
9
Shanghai
2023-09-12
Recruiting
FreeFlow Percutaneous Atrial Septal Shunt for IPAH
NCT06605794Pulmonary Arterial Hypertension
Shanghai Zhongshan Hospital
Not applicable
30
Shanghai
2023-09-11
Recruiting
Renmin Hospital of Wuhan University
Not applicable
1,460
Quanzhou, Wuhan, Shanghai
2023-09-10
Recruiting
AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
NCT06035250Gastric Cancer, Image, Pathology
Chinese Academy of Sciences
Observational
200
Beijing, Changsha, Fuzhou, Guangzhou, Kunming, Nanning, Qingdao, Shanghai
2023-09-10
Recruiting
Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma
NCT06056336Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy, Adjuvant Therapy
DrugsTislelizumab·Carboplatin
Guo Xufeng
Phase 2
73
Shanghai
2023-09-07
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
14
Shanghai
2023-09-04
Rows per page Showing 2501–3000 of 3879
Previous 4 5 6 7 8 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/city/shanghai?page=6

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 3,879 of those studies with a site in Shanghai.

How many clinical trials are recruiting in Shanghai?

2,418 of the 3,879 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 756 have not yet opened recruitment, 598 are active but closed to new participants, and 107 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.